A provision in Alaska's HB195 removes a compliance cost most pharmacy owners don't yet know about—and it takes effect in 2027.
Most Alaska pharmacy owners haven't heard about a quiet but significant change buried in HB195. Starting January 1, 2027, the state can no longer charge pharmacists fees to enter or operate under collaborative practice agreements—and state licensing boards lose the authority to regulate the scope of those agreements or require approval of them.
For independent pharmacies and small health service operators, this matters because collaborative practice agreements (CPAs) are how pharmacists legally expand their scope of work—things like administering vaccines, managing medication therapy, or providing other patient care services beyond filling prescriptions. Until now, entering a CPA could mean paying recurring fees to the state licensing board, plus navigating regulatory approval processes that varied by board and could delay implementation.
Section 4 of HB195 adds new language to Alaska Statute 08.02.150, effective January 1, 2027. The new rule is direct: no state department or licensing board can charge pharmacists any fee related to entering, maintaining, or operating under a collaborative practice agreement. The boards also lose authority to require approval of the agreement itself or to regulate its scope.
This eliminates two barriers at once. First, it removes a recurring cost. Pharmacists won't pay state fees to establish or renew CPAs. Second, it strips away regulatory gatekeeping—boards can't slow down or block agreements based on scope concerns.
The practical effect: a pharmacist or pharmacy owner considering expanded patient care services won't face state-level fees or approval delays for the collaborative agreement itself. This lowers the financial and administrative burden of diversifying services.
This applies to any pharmacist in Alaska seeking to operate under a collaborative practice agreement. It's most relevant for independent pharmacies, small chains, and rural health clinics where pharmacists take on clinical roles—immunizations, chronic disease management, medication therapy management, or other expanded services.
Larger health systems may already absorb these costs as part of broader compliance budgets, but for small operators, eliminating recurring state fees and approval requirements can meaningfully reduce barriers to service expansion.
The provision takes effect January 1, 2027. That gives pharmacy owners and managers time to understand how their state licensing board currently handles CPAs and to plan any service expansions they've been considering. Once the law is in effect, the regulatory and fee landscape changes—but the change won't be automatic. Pharmacies should monitor guidance from the Alaska Board of Pharmacy and their professional associations as the effective date approaches.
If you're evaluating whether to add clinical services—or if you've delayed doing so because of state fees or approval timelines—this provision removes one significant obstacle. The change doesn't affect federal regulations, insurance credentialing, or other requirements, but it does simplify the state-level compliance picture.
Source: HB195, Section 4, pages 3–4 (new AS 08.02.150), effective January 1, 2027.